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1. Introduction 
Studies on synthetic carbohydrates to be used as potential vaccine candidates for 
polysaccharide encapsulated bacteria were started in the mid-1970s. They were the logical 
follow-up to studies being performed at that time on the immunogenicity of antigens 
composed of carrier proteins and synthetic hapten groups. Hapten-carrier complexes were 
first introduced in immunology by Karl Landsteiner in the early 1900s [1]. He discovered 
that (i) small organic molecules with a simple structure, such as phenyl arsonates and 
nitrophenyls, do not provoke antibodies by themselves, but (ii) if those molecules are 
attached covalently, by simple chemical reactions, to a protein carrier, then antibodies 
against those small organic molecules are evoked. Since their introduction, these hapten-
carrier complexes have become excellent tools to elucidate the role of different antigen-
reactive cells in the immune response [2]. The key players in this immunological process are 
thymus-derived T cells and bone marrow-derived B cells. The former group of lymphoid 
cells is responsible for various phenomena of cell-mediated immunity, e.g. delayed 
hypersensitivity, allograft-, and graft-versus-host reactions, and reacts with specific 
determinants on the carrier protein (T cell epitopes). The latter group of lymphoid cells (B 
cells) give rise to the precursors of antibody-secreting cells, and reacts with both the carrier 
protein and the synthetic haptenic determinants. This results in antibody formation to both 
the carrier and the hapten. 
The reason to apply the above concepts and techniques to carbohydrate antigens was to 
address an immunological problem: polysaccharide molecules are classified as so-called 
thymus-independent (TI) antigens, because they do not require T cells to induce an immune 
response of B cells. As a result, the antibodies formed are mainly of the IgM class and have a 
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low avidity. Moreover, no immunological memory is generated and the antigens are poorly 
immunogenic in infants. Latter characteristic has major implications for development of 
vaccines against polysaccharide encapsulated bacteria. It was hypothesized that by linking 
small carbohydrates (oligosaccharides) to a carrier protein, the immunogenic behavior 
would change to that of a thymus-dependent (TD) antigen. Therefore, the studies of both 
Goebel [3, 4] and Campbell and Pappenheimer [5], who first isolated the antigenic 
determinant of Streptococcus pneumoniae type 3, were combined and extended. The hapten-
inhibition studies by Mage and Kabat [6] demonstrated that the antibody-combining site of 
type 3 pneumococcal polysaccharide consists of two to three cellobiuronic acid units. In the 
dextran-anti-dextran system extensively studied by Kabat and colleagues [7] the upper size 
limit of the antibody-combining site appeared to be a hexa- or heptasaccharide and the lower 
limit was estimated to be somewhat larger than a monosaccharide. Snippe and colleagues [8] 
proved in 1983 that small synthetic oligosaccharides (tetra- and hexasaccharides) of S. 
pneumoniae type 3 could be transformed into TD antigens by conjugating them to a protein 
carrier. This opened the way to explore the synthesis and immunogenicity of numerous 
oligosaccharide-carrier protein conjugates of different pneumococcal serotypes. Those 
studies culminated in 2004 in the large-scale synthesis and introduction of a synthetic 
oligosaccharide vaccine for Haemophilus influenzae type b for use in humans in Cuba [9]. The 
recent exploration of gold nanoclusters coated with synthetic oligosaccharides and peptides 
as a vaccine are a promising platform towards the development of fully synthetic 
carbohydrate-based vaccines [10]. 
2. Streptococcus pneumoniae 
Streptococcus pneumoniae (S. pneumoniae or pneumococcus) is a leading cause of bacterial 
pneumonia, meningitis, and sepsis in children worldwide. It is estimated that 1.6 million 
people die from these infections each year, of whom one million are children [11, 12]. S. 
pneumoniae are lancet-shaped, gram-positive, and alpha-hemolytic bacteria that colonize the 
mucosal surfaces of the upper respiratory tract [13]. Three major surface layers can be 
distinguished from the inside to the outside: the plasma membrane, the cell wall, and the 
capsule (Fig. 1) [14]. The cell wall consists of a triple-layered peptidoglycan backbone that 
anchors the capsular polysaccharide, the cell wall polysaccharide, and also various proteins 
such as pneumococcal surface protein A (pspA) and hyluronate lyase (Hyl) (Fig. 1). The 
capsule is the thickest layer, completely concealing the inner structures of exponentially 
growing S. pneumoniae bacteria.  
3. Capsular polysaccharide 
Capsular polysaccharides are well known as the major virulence factors of S. pneumoniae. 
Today more than 92 serotypes have been identified based on the different chemical structures 
of these polysaccharides [16, 17]. This diversity determines the ability of the serotypes to 
survive in the bloodstream and very likely the ability to cause invasive disease, especially in 
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the respiratory tract [14, 16]. Recently, new S. pneumoniae serotypes have been identified, e.g. 
serotype 6C [17], 6D [18, 19], and 11E [20]. Capsular polysaccharides are large polymers (0.5-
2x106 Da), composed of multiple repeating units of up to eight sugar residues [14]. The 
capsular polysaccharides are generally synthesized by the Wzx/Wzy-dependent pathway, 
except for type 3 and 37 which are synthesized by the synthase pathway [21, 22] (Fig. 2). In 
the synthase pathway capsule is produced through processive transferase activity [23, 24].  
 
Figure 1. Schematic structure of S. pneumoniae. StrA=sortase A. Hyl=hyluronate lyase. 
PavA=pneumococcal adhesion and virulence. Eno=enolase. NanA=neuraminidase. PsrP=pneumococcal 
serine-rich repeat protein. LytA=autolysin. LTA=lipoteichoic acid. PspA=pneumococcal surface protein 
A. PspC=pneumococcal surface protein C. PiaA/PiuA=pneumococcal iron acquisition and uptake. 
PsaA=pneumococcal surface antigen A. (Adopted from van der Poll, T. and Opal, S.M. [15] and de 
Velasco, E.A. et al [14]) 
Many studies have demonstrated that antibodies directed against the capsular 
polysaccharide are essential for protection against pneumococcal disease [25-27]. However, 
the native capsular polysaccharides are well-known thymus-independent type-2 (TI-2) 
antigens that lack T-helper epitopes and therefore mainly induce IgM antibodies, and to a 
lesser degree IgG [28]. The TI-2 characteristics of polysaccharides can be altered by 
conjugation of polysaccharide to a protein carrier (glycoconjugate) resulting in a switch to 
an anti-polysaccharide antibody response with characteristics of a T-cell-dependent 
response. This is reflected by the generation of memory B and T cells and the induction of 
high titers of anti-polysccharide IgG antibodies after booster immunization [29]. 
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It should be noted that not all polysaccharides behave as TI-2 antigens. Zwitterionic 
polysaccharides such as S. pneumoniea type 1 polysaccharide: [3)--AATGal-(14)--D-
GalpA-(13)--D-GalpA-(1]n with a right-handed helix with repeated zwitterionically 
charged grooves elicit potent T cell responses in vivo and in vitro [30, 31].  
 
Figure 2. Representation of the Wzx/Wzy-dependent pathway for biosynthesis of CPS 9A (Adopted 
from Bentley. S.D. et al [21]). Representation of the Wzx/Wzy-Dependent Pathway Pictured is a 
hypothetical model for capsule biosynthesis in S. pneumoniae based on a mixture of experimental 
evidence and speculation.  
1. Non-housekeeping nucleotide sugar biosynthesis. 
2. The initial transferase (WchA in this case) links the initial sugar as a sugar phosphate 
(Glc-P) to a membrane-associated lipid carrier (widely assumed to be undecaprenyl 
phosphate). 
3. Glycosyl transferases sequentially link further sugars to generate repeat unit. 
4. Wzx flippase transports the repeat unit across the cytoplasmic membrane. 
5. Wzy polymerase links individual repeat units to form lipid-linked CPS. 
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6. Wzd/Wze complex translocates mature CPS to the cell surface and may be responsible 
for the attachment to peptidoglycan.  
4. Development of pneumococcal vaccines 
Although the first pneumococcal vaccines, including the application of the principle of 
conjugate vaccination, were already initiated in the beginning of the previous century, most 
of these developments stopped when antibiotics were introduced. Existing vaccines were 
even withdrawn from the market. By now, in many parts of the world, the antibiotic 
resistance of S. pneumoniae bacteria has increased: America [32, 33], Africa [34], Europe [35, 
36], Asia [37-39], and Australia [40]. This makes treatment of pneumococcal infections more 
difficult and stresses the importance of the development of effective vaccines as a strategy to 
reduce morbidity and mortality caused by S. pneumoniae infection worldwide. 
4.1. Pneumococcal polysaccharide-based vaccines. 
Currently two vaccine types against S. pneumoniae are commercially available: a 
pneumococcal polysaccharide vaccine (PPV) and a pneumococcal conjugate vaccine (PCV) 
[41]. The first multivalent pneumococcal polysaccharide vaccine (PPV) contains 23 purified 
capsular polysaccharides (25 µg of each capsule type; Pneumovax®, PPV23: 1, 2, 3, 4, 5, 6B, 7, 
8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 15F, 18C, 19A, 19F, 20, 22F, 23F, 33F ) which is licensed for 
use in adults and children older than 2 years of age [42]. This vaccine was shown to be 
moderately effective in young adults [43] but not in young children [44] and elderly [45] and 
also not in immunocompromised patients, e.g HIV infected people [46, 47].  
In early 2000, a polysaccharide-protein conjugate vaccine targeting seven pneumococcal 
serotypes was licensed in the United States for use in young children (Prevnar, PCV7: 4, 6B, 
9V, 14, 18C, 19F, 23F). The polysaccharides are conjugated to the non-toxic cross reactive 
material from diphtheria toxin, CRM197 and each dose contains 2µg of each capsule type, 
except for 6B, for which 4 µg is included in every vaccine dose[48]. The PCV7 vaccine 
produces a significant effect regarding prevention of invasive pneumococcal disease in 
children younger than 24 months (based on a meta-analysis of published data from trials on 
pneumococcal vaccine) [49]. Large scale introduction of PCV7 has resulted in an overall 
decline in infectious pneumococcal disease (IPD). However, IPD caused by the non-vaccine 
serotypes serotypes 1, 19A, 3, 6A, and 7F has increased (replacement disease), highlighting 
the need for inclusion of these serotypes in future improved vaccine formulations [50]. 
Apart from the CRM197 based PCV7, several new candidate pneumococcal conjugate 
vaccines have been developed to cover more serotypes with different protein carriers and 
most of them are in clinical trials, such as PCV10 vaccine (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 
23F) [51, 52] and PCV13 vaccine (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) [53]. 
4.2. Pneumococcal protein-based vaccines 
An alternative vaccine strategy focuses on the use of pneumococcal surface-associated 
proteins which are to be assumed to elicit protection in all age groups against all, or nearly 
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all, pneumococcal serotypes (Fig. 1). Protection induced by the proteins should be serotype-
independent and possibly cheaper and thus within reach of developing countries [54]. 
Currently, several surface pneumococcal proteins are investigated as a candidate vaccine 
against S. pneumoniae infection with single or combination of recombinant proteins, such as 
pspA family fusion protein [55]; pneumolysis and pspA1/pspA2 combined [56]. Recently 
new candidate protein antigens were discussed at the 8th International Symposium on 
Pneumococci and Pneumococcal Diseases at Iguaçu Falls, Brazil (2012), phtD (pneumococcal 
histidin triad protein D) and PcpA (pneumococcal choline binding protein A) [57]. 
4.3. Pneumococcal synthetic oligosaccharide-based vaccines 
The current polysaccharide conjugate vaccines are based on natural polysaccharides, purified 
form bacterial cultures. Synthetic oligosaccharide–protein conjugates (neoglycoconjugate), 
involving functional mimics of the natural polysaccharide antigens have emerged as an 
attractive option [58]. The advantages of neoglycoconjugates are well-defined chemical 
structures (chain length, epitope conformation, and carbohydrate/protein ratio) as well as a 
lack of the impurities present in polysaccharides obtained from bacterial cultures [59, 60].  
The chemical synthesis of oligosaccharide fragments however is complex. According to the 
sequence in the natural polysaccharide, monosaccharide residues have to be linked in such a 
way that they form an oligosaccharide with the required stereospecificity (epitope). Various 
methodologies and strategies for synthesis of carbohydrates have successfully been used for 
production of experimental neoglycoconjugates, as reviewed by Kamerling [16]. In 2001, the 
first automated synthesis of oligosaccharides was reported by Plante, O.J. et al [61].  
Neoglycoconjugates have been prepared for saccharides of different microorganisms. In 2004, 
Verez Bencomo et al., reported the large-scale synthesis and the introduction of a synthetic 
oligosaccharide vaccine for Haemophilus influenzae type b for use in humans in Cuba [9]. The 
immunogenicity of the synthetic oligosaccharide fragment of the O-specific polysaccharide 
(O-PS) of Vibrio cholera O1, serotype Ogawa, conjugated to bovine serum albumin has been 
investigated in a mouse model [62, 63]. A multimeric bivalent synthetic hexasaccharide 
fragment of the O-specific polysaccharide of Vibrio cholera O1, serotype Ogawa, in 
combination with Inaba:1 or a synthetic disaccharide tetrapeptide peptidoglycan fragment as 
adjuvant were prepared and conjugated to recombinant tetanus toxin H(C) fragment as 
protein carrier [64]. The immunogenicity of synthetic oligosaccharides mimicking the O-
antigen of the Shigella flexneri 2a lipopolysaccharide (LPS) was also investigated in mice [65, 
66]. Immunization of mice with synthetic hexasaccharide of glycosylphosphatidylinositol 
malarial toxin conjugated to a protein carrier was reported to protect the mice from an 
otherwise lethal dose of malaria parasites [67]. A fully synthetic carbohydrate-based 
antitumor candidate vaccine for the common T-synthase was recently reported [68]. 
Meanwhile we and other groups have been working on improving the immunogenicity of 
neoglycoconjugates against different S. pneumoniae serotypes in animal models: Di-, tri-, and 
tetrasaccharides related to polysaccharide type 17F conjugated to keyhole limpet 
hemocyanin (KLH) protein[69, 70] and tri- and tetrasaccharides related to type 23 
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conjugated to KLH protein [71]; Di-, tri-, and tetrasaccharides related to type 6B conjugated 
to KLH protein [72]; Di-, tri-, and tetrasaccharide related to type 3 conjugated to the cross-
reactive material of diphteria toxin (CRM197) protein [60] and most recently overlapping 
oligosaccharide varying from tri- to dodecasaccharides related to polysaccharide type 14 
conjugated to CRM197 protein [73, 74]. 
5. Immunogenicity of synthetic oligosaccharide based vaccines 
This review focuses on the S. pneumoniae type 14 capsular polysaccharide (Pn14PS) which 
consists of biosynthetic repeating units of the tetrasaccharide {6)-[-D-Galp-(1→4)-]-D-
GlcpNAc-(13)--D-Galp-(1→4)--D-Glcp-(1→}n [75] (Fig. 3).  
 
Figure 3. A branched tetrasaccharide repeating unit of S. pneumoniae type 14 capsular polysaccharide 
(A) and its nomenclature symbol (B): filled circle = glucose (Glc); open circle = galactose (Gal), and filled 
square = N-acetylglucosamine (GlcNAc) 
5.1. Identification of the minimal structure of oligosaccharide capable in evoking 
anti-Pn14PS antibodies.  
It was reported that a synthetic branched tetrasaccharide, corresponding to a single 
structural repeating unit of Pn14PS conjugated to the cross-reactive material of diptheria 
toxin (CRM197), was found to induce anti-polysaccharide type 14 antibodies by Mawas, F. et 
al [74]. We continued to investigate further how small the minimal structure in Pn14PS can 
be and still produce specific antibodies against native polysaccharide type 14 [73]. 16 
overlapping oligosaccharide fragments of Pn14PS were synthesized as described previously 
[76-79] and were conjugated to the protein carrier CRM197. The mice immunization studies 
were performed to investigate the immunogenicity of the neoglycoconjugates. We found 
that the fragments with a linear and/or incomplete branched structure did not elicit specific 
antibodies against native Pn14PS (Fig. 4: JJ118, JJ42, JJ141, DM65, JJ153, JJ9, JJ6 and DM35) 
[73]. High titer of anti-Pn14PS IgG antibodies was observed when the complete branched 
structure fragments, conjugated to the protein carrier were used in the mouse model (Fig. 4: 
JJ1, DM66, DM36, ML1, ML2, and CRM197-Pn14PS as a positive control), excepted for JJ5 and 
JJ10 which elicited low titer of anti-Pn14PS antibodies.  
We also tested the phagocytic capacity of mice sera by human polymorph nuclear cells and 
a mouse macrophage cell line. We found that the sera containing antibodies against Pn14PS 
were also capable of promoting the phagocytosis of S. pneumoniae type 14. Conjugates that 
did not evoke specific antibodies against polysaccharide type 14 also did not display 
phagocytic capacity [73].  
 The Complex World of Polysaccharides 624 
 
Figure 4. Level of anti-Pn14PS antibodies and schematic structure of overlapping synthetic 
oligosaccharide fragments of Pn14PS (Adopted from Safari et al 2008 [73]). The oligosaccharides were 
conjugated to CRM197 protein and the immunogenicity of those conjugates were studies in a mouse model. 
Mice were immunized with polysaccharide type 14 conjugated to CRM197 (CRM197-Pn14PS) as a positive 
control. Enzyme-linked immunosorbent assay was employed to measure specific anti-Pn14PS IgG 
antibodies after the booster immunization. Antibody titers were expressed as the log10 of the dilution Filled 
circle = glucose (Glc); open circle = galactose (Gal), and filled square = N-acetylglucosamine (GlcNAc).  
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In conclusion, the present study has shown that the branched trisaccharide Glc-(Gal-)GlcNAc 
is the core structure inducing Pn14PS-specific antibodies and that the neighboring galactose 
at the non-reducing end significantly contributes to the induction of phagocytosis-
promoting antibodies [73]. Our study provides evidence that the branched tetrasaccharide 
Gal-Glc-(Gal-)GlcNAc is a prime candidate for a synthetic oligosaccharide conjugate vaccine 
against infections caused by S. pneumoniae type 14 [73]. 
5.2. Relationship between polysaccharide of Pn14PS and GBSIII 
We also determined the minimal epitope in group B streptococcus type III polysaccharide 
(GBSIIIPS), using both a panel of anti-Pn14PS mouse sera and sera of humans vaccinated with 
either Pn14PS or GBSIIIPS as reported by Safari et al [80]. Native Pn14PS is structurally related 
to and has cross-reactivity with GBSIIIPS [81]. The branched structures of Pn14PS and 
GBSIIIPS differ only in the absence (in Pn14PS) or presence (in GBSIIIPS) of the (α23)-linked 
sialic acid N-acetylneuraminic acid (Neu5Ac) in their side chains: {→4)-β-D-Glcp-(1→6)-[±α-
Neu5Ac-(23)-β-D-Galp-(14)-]β-D-GlcpNAc-(1→3)-β-D-Galp-(1→}n [82]. We reported that 
type-specific Pn14PS antibodies which recognize the branched structure of Pn14PS have a low 
affinity for the native GBSIIIPS and do not promote opsonophagocytosis of GBSIII, however 
desialylation of GBSIIIPS, however, resulted in dramatically higher affinity of anti-Pn14PS 
antibodies in mice when GBSIIIP was treated by nurimindase (desialylation) [80]. These results 
revealed that GBSIII bacteria are protected from binding of antibodies against Pn14PS by a 
residue of (α23)-linked sialic acid, as described previously [83, 84]. 
5.3. Booster immunization either with either neoglycoconjugate or native 
polysaccharide 
We investigated further the immune response to a neoglycoconjugate of Pn14PS (GC) on the 
outcome of sustained immunity to S. pneumoniae type 14 in a mouse model after the booster 
injection with either (GC) or native Pn14PS (PS) [85]. We found, as we expected, that the 
amount of specific IgG antibodies against Pn14PS increased substantially when a GC booster 
was given to mice previously primed with the same GC [85]. The induced antibodies were 
capable to opsonise S. pneumoniae type 14. Boosting with PS following a primary conjugate 
vaccine injection did not result in IgG antibody formation to Pn14PS (Table 1).  
In order to explain these phenomena we investigated how a booster immunization with a 
GC or PS affects the cell-mediated immune response by measuring the production profile of 
a panel of cytokines [85]. We observed a high level of IL-5 in serum after a booster injection 
with GC (GC-GC or GC-GC-GC). Boosting with PS did not result in the induction of IL-5 
nor of any of the other tested cytokines (Table 1; GC-PS and GC-PS-PS). We conclude that 
induction of the cytokine IL-5 in serum is an early sign of a successful booster immunization 
and is a prerequisite for the production of specific anti-polysaccharide IgG antibodies [85]. 
In-vitro spleen cell cultures were also used to investigate the effect of a booster injection on 
activation of memory T cells. IL-5 which well known Th2 cytokines, were evoked by the GC 
in spleen cell cultures of mice previously primed and boosted with the same GC [85]. In 
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conclusion, the inability of polysaccharide to boost primed mice might be due to the 
incapability to induce the cytokines. 
 
Immunization1 
IgG titer 
(Log10)2 
Level of Cytokine IL-5 (pg/ml) 
In serum3 After stimulation4 
GC-GC 2.18±0.22 1022.3±275.2 571.2±20.0 
GC-PS 0.34±0.47 0.3±0.5 66.1±0.4 
GC-GC-GC 3.02±0.17 2700.4±112.3 1172.8±7.1 
GC-PS-PS 0.0 0.0 664.9±221. 
Saline 0.0 6.9±1.1 0.0 
1Five mice per group were immunized with a CRM-neoglycoconjugate (GC), a synthetic branched tetrasaccharide of 
Pn14PS that is conjugated to a CRM197 protein. Booster doses containing either a GC (GC-GC and GC-GC-GC) or a 
native polysaccharide of Pn14PS (PS) (GC-PS, GCGC-PS, and GC-PS-PS) were injected at Weeks 5 and 10. 
2ELISA was employed to measure specific anti-Pn14PS IgG antibodies, and expressed as the log10 of the sera dilution 
3Cytokine levels in sera from mice receiving booster injection. Sera were collected on Day 1 after the primary immunization 
4Splenocytes were isolated 7 days after the first booster injection. Spleen cells were cultured in vitro and stimulated 
with CRM-neoglycoconjugate and supernatants were collected 72 h after culture initiation.  
Table 1. Effect of booster immunization either with with either the same neoglycoconjugate or a native 
polysaccharide (Adopted from Safari, D. el at [85] with permission) 
5.4. Improvement of anti-Pn14PS antibodies level by coadjuvant administration 
The immunogenicity of neoglycoconjugate was increased with adjuvant coadministration 
[73, 86]. We set out to investigate in a mouse model the effect of adjuvant coadministration 
i.e. Quil-A, MPL, DDA, CpG and Alum on both the antibody- and cell-mediated immune 
response against a neoglycoconjugate as reported by Safari et al [87]. In the absence of 
adjuvant, immunization with neoglycoconjugate leads after a booster merely to IgG1 
antibodies against PnP14PS. Coadministration of adjuvant had multiple effects: a diversified 
anti-Pn14PS IgG antibody response (also other IgG subclasses than IgG1 were evoked), an 
enhanced avidity and increased opsonic activity of these antibodies [87]. We found that next 
to Quil-A also DDA as a single dose or in combination with CpG had similar effects on the 
diversification of eliciting a broader variety of anti-Pn14PS IgG antibody subclasses. 
Meanwhile, CpG or alum on their own showed in majority IgG1 antibodies after booster 
immunization in a same pattern as in non adjuvant groups [87]. Compared to other 
adjuvants, codelivered Quil-A strongly improved the antibody avidity and enhanced the 
phagocytosis of S. pneumoniae type 14 [87]. 
6. Future researches 
In this review, synthetic oligosaccharide-protein conjugates are proven to be effective 
vaccines in mice model. A logical next step would be a feasibility and immunogenicity 
study in human volunteers. Before that, a study should be started with synthetic 
oligosaccharide-protein conjugates for at least the pneumococcal serotypes 1, 4, 5, 9V and 
18C and should even have been completed, because the minimal epitopes for these 
polysaccharides are still unknown. 
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To improve the immunogenicity of oligosaccharide-protein conjugates co-delivery of 
adjuvants are required. As an alternative to the addition of adjuvants, studies should be 
initiated to direct oligosaccharide-protein conjugates to dendritic cells by incorporation of 
specific ligands. Targeting to and activation of dendritic cells by TLR5 is a possibility to be 
explored. 
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